These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32503989)

  • 21. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines.
    Waheed MT; Thönes N; Müller M; Hassan SW; Razavi NM; Lössl E; Kaul HP; Lössl AG
    Transgenic Res; 2011 Apr; 20(2):271-82. PubMed ID: 20563641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
    Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
    Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
    Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
    Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-generation prophylactic HPV vaccines: successes and challenges.
    Tyler M; Tumban E; Chackerian B
    Expert Rev Vaccines; 2014 Feb; 13(2):247-55. PubMed ID: 24350614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R; Zhai L; Tumban E
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
    Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S
    J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional assessment and structural basis of antibody binding to human papillomavirus capsid.
    Zhang X; Li S; Modis Y; Li Z; Zhang J; Xia N; Zhao Q
    Rev Med Virol; 2016 Mar; 26(2):115-28. PubMed ID: 26676802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
    Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
    Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
    Godi A; Bissett SL; Miller E; Beddows S
    J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.
    Módolo DG; Araldi RP; Mazzuchelli-de-Souza J; Pereira A; Pimenta DC; Zanphorlin LM; Beçak W; Menossi M; de Cassia Stocco R; de Carvalho RF
    Vaccine; 2017 Mar; 35(12):1590-1593. PubMed ID: 28222997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.